Opinion

Video

Future Directions in the Management of Multiple Myeloma

Author(s):

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma.

Video content above is prompted by the following questions:

  1. Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues.
  2. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma? What can we look forward to through the end of the year and beyond?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
Pieter Sonneveld, MD, PhD
1 expert in this video
1 expert in this video
Pieter Sonneveld, MD, PhD
Ajai Chari, MD
1 expert in this video
1 expert in this video
Related Content
IVBM Phoenix logo | Image: AJMC
May 19th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

Laura Joszt, MA
AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD
Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Health equity concept | image credit: VectorMine - stock.adobe.com
April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
Targeting GPRC5D Holds Promise in Multiple Myeloma
April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.
Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser
The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo